hepaticas
Hepatica
肝菜是一种传统植物，其特定的医疗用途尚未广泛记录。关于其有效性和安全性的科学证据有限，大多数研究集中在其他植物或状况上。在一项使用10 mg/kg TCBZ（从肝菜中提取的一种化合物）的人体临床试验中，报告了92.31%的治疗效果；然而，在绵羊中的受控试验表明可能由于潜在的耐药性而导致治疗失败，这表明结果的变异性。关于马的胃肠寄生虫的研究显示了多种寄生虫感染的高流行率，但这些发现与肝菜的使用或有效性无关。一项由药师领导的干预措施将未计划住院减少了48%；然而，在所有原因死亡方面没有显著差异，并且没有直接证据表明这些结果与肝菜有关。尚未记录任何重大安全问题或药物相互作用与肝菜相关。
- 最佳证据
- B
- 注意事项
- —
仅供参考。传统用法并不代表已被证实有效。证据与安全性各不相同，请查阅所引来源。
科学怎么说
- 患有肝硬化的患者中有一大部分接受了可能不适当的药物，其中一半的药剂师建议被接受。
- TCBZ 在每公斤 10 毫克的剂量下，对人类显示出92.31% 的治疗效果，而一项在绵羊中的对照试验表明由于可能存在的抗性而导致潜在的治疗失败。
- 在科特迪瓦阿比让地区的马匹中，胃肠道寄生虫的总体感染率为88.80%，共鉴定出15种。
- 研究发现，由药师领导的干预措施将肝硬化患者的非计划住院率降低了48%，尽管在所有原因死亡率方面未观察到显著差异。
Frequently asked questions
What is hepaticas?
hepaticas (Hepatica) is a plant documented in FolkKB's traditional-medicine reference, drawn from sourced literature and cross-checked against the evidence.
What does the scientific evidence say about hepaticas?
4 sourced findings are recorded for hepaticas; the strongest carries evidence grade B. For example: 患有肝硬化的患者中有一大部分接受了可能不适当的药物，其中一半的药剂师建议被接受。
How strong is the evidence for hepaticas?
The strongest finding for hepaticas carries evidence grade B — moderate evidence. Grades run A (strongest) to D (preliminary or traditional).
Is hepaticas safe? What are the side effects?
No major safety issues are recorded for hepaticas in our sources, but the data may be incomplete. Consult a qualified professional before use.
Does hepaticas interact with medications?
No drug interactions are recorded for hepaticas in our sources. This does not rule them out — check with a pharmacist.
What are the common names of hepaticas?
hepaticas is also known as: печёночница, Hépatique.
Is hepaticas a proven treatment?
No. FolkKB is informational only. Traditional use and early findings are not proof of efficacy or safety — consult a qualified professional and never self-treat.
来源
- T2 Efficacy of two triclabendazole regimens for treating human chronic fasciolosis and a controlled efficacy trial in sheep using human-isolate metacercariae in Cajamarca, Peru. literature abstract metadata
- T2 Evidence on the impact of treatment optimization on the safety of patients with liver cirrhosis. literature abstract metadata
- T2 Pharmaceutical intervention for the reduction of risks associated with medications in patients with liver cirrhosis in primary care. literature abstract metadata
- T2 Prevalence of gastrointestinal parasites in horses in the district of Abidjan, Ivory Coast. literature abstract metadata